20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Zura Bio Limited Class A Ordinary Shares (ZURA) operates in the BIOTECHNOLOGY industry and is headquartered in Henderson, United States with about 40 employees. Its market capitalization is roughly $389 million. In the fiscal year ended 2025-12-31, ZURA reported $0M in revenue and ($69M) in net income.
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | — |
| Gross Profit | — | $0M | $0M | — | — | — |
| Gross Margin % | — | — | — | — | — | — |
| Operating Income (EBIT) | ($93M) | ($75M) | ($55M) | ($63M) | ($27M) | ($1M) |
| Operating Margin % | — | — | — | — | — | — |
| Net Income | ($86M) | ($69M) | ($52M) | ($60M) | ($26M) | $8M |
| Net Margin % | — | — | — | — | — | — |
| EBITDA | ($86M) | ($69M) | ($52M) | ($61M) | ($27M) | $8M |
| Earnings Per Share (EPS) | $-0.80 | $-0.73 | $-0.70 | $-1.83 | $-1.49 | $0.49 |
| Shares Outstanding (M) | 127M | 94M | 75M | 33M | 17M | 17M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | -250.0% | — |
| Operating Income (EBIT) | ($29M) | ($29M) | ($25M) | ($18M) | ($20M) | ($18M) | ($19M) | ($16M) | ($19M) |
| Operating Margin % | — | — | — | — | — | — | — | -786600.0% | — |
| Net Income | ($26M) | ($26M) | ($24M) | ($17M) | ($18M) | ($16M) | ($17M) | ($9M) | ($21M) |
| Net Margin % | — | — | — | — | — | — | — | -452400.0% | — |
| EBITDA | — | ($26M) | ($24M) | ($17M) | ($18M) | ($16M) | ($17M) | ($14M) | ($21M) |
| Earnings Per Share (EPS) | $-0.20 | $-0.21 | $-0.22 | $-0.18 | $-0.19 | $-0.17 | $-0.27 | $-0.14 | $-0.24 |
| Shares Outstanding (M) | — | 127M | 112M | 94M | 95M | 94M | 65M | 65M | 87M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($78M) | ($65M) | ($28M) | ($15M) | ($1M) | ($1M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $8M | $12M | $0M |
| Free Cash Flow (FCF) | ($78M) | ($65M) | ($28M) | ($23M) | ($13M) | ($1M) |
| FCF Margin % | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($20M) | ($21M) | ($19M) | ($22M) | ($15M) | ($16M) | ($11M) | ($11M) | ($6M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($20M) | ($21M) | ($19M) | ($22M) | ($15M) | ($16M) | ($11M) | ($11M) | ($6M) |
| FCF Margin % | — | — | — | — | — | — | — | -543450.0% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-09-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Total Assets | $195M | $114M | $180M | $101M | $5M | $141M |
| Cash & Cash Equivalents | $188M | $109M | $176M | $100M | $2M | $1M |
| Total Liabilities | $17M | $12M | $20M | $21M | $27M | $10M |
| Total Debt (Short + Long-Term) | — | $0M | $0M | $0M | $8M | $0M |
| Total Shareholders' Equity | $178M | $102M | $147M | $59M | ($32M) | $130M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ZURA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms